SCHEMBL23217244

SCHEMBL23217244

CCOC(=O)CC(=O)[C@H]1C[C@H](c2c(OC)ccc(Cl)c2Cl)CN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.39
HTR2C P28335 4/20 0.39
HTR2B P41595 4/20 0.39
ALDH1A1 P00352 3/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 2/20 0.35
DRD2 P14416 2/20 0.35
KDM4E B2RXH2 2/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
S1PR1 P21453 1/20 0.32
TSHR P16473 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29844519 0.88 HTR2A (0.38) HTR2AHTR2CHTR2BALDH1A1PKM
SCHEMBL23227411 0.88 HTR2A (0.38) HTR2AHTR2CHTR2BALDH1A1PKM
SCHEMBL23217482 0.84 HTR2A (0.38) HTR2AHTR2CHTR2BALDH1A1PKM
SCHEMBL23217172 0.83 HTR2C (0.44) HTR2AHTR2CHTR2BDRD2
SCHEMBL23217480 0.83 HTR2C (0.44) HTR2AHTR2CHTR2BDRD2
SCHEMBL23217364 0.82 HTR2C (0.43) HTR2AHTR2CHTR2BPKMDRD2
SCHEMBL21053552 0.81 ALDH1A1 (0.34) ALDH1A1KDM4EPOLBSMN1; SMN2MEN1
SCHEMBL21054669 0.81 ALDH1A1 (0.34) ALDH1A1KDM4EPOLBSMN1; SMN2MEN1
SCHEMBL23217113 0.80 HTR2C (0.41) HTR2AHTR2CHTR2BALDH1A1DRD2
SCHEMBL23217319 0.79 DRD2 (0.38) HTR2AHTR2CHTR2BALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114828963-A Arylheterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-29 CN disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 HTR2A 1799/4885HTR2C 1162/4885HTR2B 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.